Vyant Bio (VYNT) Reports Q1 Loss from Cont. Operations of $0.15

Vyant Bio (NASDAQ: VYNT) reported Q1 EPS from continuing operations of ($0.15), versus the consensus of ($0.16). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $300 thousand.

Cash and cash equivalents totaled $16.4 million as of March 31, 2022.

For earnings history and earnings-related data on Vyant Bio (VYNT) click here.

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• Fastenal (FAST) Reports In-Line Q2 EPS, Beats on Revenue
• Cantor Fitzgerald: MKS Instruments (MKSI) 'Remains Our Top Pick Within the SMID Cap Space'